Shots:
- The company has initiated patient enrolment in P-III ULTRA-V trial evaluating Ukoniq + ublituximab + venetoclax, vs Ukoniq + ublituximab (U2) in patients with both frontline and r/r CLL. The 1EPs of the trial is PFS
- The company reports the completion of patient enrolment in the P-II ULTRA-V trial evaluating the triple combination of U2 + venetoclax in 165 patients with front line CLL, r/r CLL who were refractory to prior BTK therapy. The 1EPs of the trial is ORR and CRR
- The company launch a P-III study based on the P-I clinical results. Additionally, the initial results from the P-II ULTRA-V trial are expected in 2022
Click here to read full press release/ article | Ref: TG Therapeutics | Image: Seeking Alpha
The post TG Therapeutics Initiates Patient Enrolment in P-III ULTRA-V Trial for Triple Combination Regimen to Treat R/R Chronic Lymphocytic Leukemia first appeared on PharmaShots.
